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Abstract  
 
Background and Purpose 
To determine the safety and tolerability of dose-escalation using modestly 
accelerated IMRT in high-risk locally advanced thyroid cancer requiring post-
operative radiotherapy, and to report preliminary data on efficacy. 
 
Materials and Methods 
A sequential Phase I dose-escalation design was used. Dose level one (DL1) 
received 58.8 Gy/28F to the post-operative bed and 50 Gy/28F to elective nodes. 
DL2 received 66.6 Gy/30F to the thyroid bed, 60 Gy/30F to post-operative nodal 
levels and 54 Gy/30F to elective nodal levels. Acute (NCICTCv.2.0) and late 
toxicities (RTOG and modified LENTSOM) were recorded. The primary endpoint was 
the number of patients with ≥ Grade 3 (G3) toxicity at 12 months post-
treatment. 
 
Results  
Fifteen patients were recruited to DL1 and twenty-nine to DL2.  At 12 months, ≥ G3 
toxicities were 8.3% in both DL1 and DL2. At 60 months, ≥ G3 toxicity was 
reported in 3 (33%) patients in DL1 and 1 (7%) in DL2. One patient in DL2 died at 
24 months from radiation-induced toxicity. Time to relapse interval and overall 
survival rates were higher in DL2, but this was not statistically significant .  
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Dose-escalation using this accelerated regimen can be safely performed with a 
toxicity profile similar to reported series using conventional doses.  
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Introduction 
 
External beam radiotherapy is used in high-risk thyroid cancer postoperatively to 
reduce the risk of recurrence and increase the likelihood of achieving locoregional 
control [1]. 
Dosimetric planning studies have demonstrated that intensity-modulated 
radiotherapy reduces dose to organs-at-risk in thyroid cancer while maintaining PTV 
coverage [2]. 
There has been no prospective trial assessing dose-fractionation in thyroid cancer, 
although retrospective series suggest a dose-response curve [3].  
It is generally accepted that a dose of 60 Gy in 30 fractions or a biologically 
equivalent dose is required, although some centres have explored the use of boosts 
above this to the at-risk areas [4], [5]. 
 
We have previously reported acute toxicities in DL1 of the study investigating the 
effect of modest acceleration using IMRT to deliver 58.8 Gy in 28 fractions to tumour 
bed or involved nodal sites and 50 Gy in 28 fractions to elective nodes [6]. This was 
well tolerated with one G3 toxicity and the trial proceeded to DL2 with an expanded 
dose-escalated cohort. This cohort received 66.6 Gy in 30 fractions to the primary 
tumour bed, 60 Gy in 30 fractions to the involved nodes and 54 Gy in 30 fractions to 
the elective nodes. The aim of this sequential Phase I study was to assess the safety 
and tolerability of dose-escalation using IMRT, and gain preliminary data on efficacy. 
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We have previously reported the acute toxicities of the expanded cohort, which 
were similar between the two groups [7]. We now report the long-term toxicity and 
survival outcomes at five years.  
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Materials and Methods 
 
Study objectives and patient eligibility 
Patients with histologically proven, locally advanced differentiated and medullary 
thyroid carcinoma with radiological and pathological features warranting post-
operative external beam radiotherapy were eligible (T4 disease; positive neck 
nodes; recurrent disease; residual macroscopic disease or medullary carcinoma). 
Patients aged <18 years or with an anaplastic thyroid cancer were excluded. Pre-
treatment evaluations comprised history, examination, pre-operative computed 
tomography of head, neck and chest, optimal surgical resection and institutional 
pathological review. The disease was staged according to AJCC 1997 criteria. All 
patients provided written informed consent and the Institutional Research and 
Ethics Committee approved the study (Royal Marsden Hospital CCR 1978, 
NCT02055989).  
 
Trial design 
A sequential cohort Phase I dose-escalation design was used. This was a single 
institution study with standard departmental protocol used for target volume 
delineation. The aim of the first phase was to determine feasibility of using IMRT 
in delivering a modestly accelerated fractionation regimen. Dose-escalation 
followed once feasibility was demonstrated in the Phase I study. Initially, 15 
patients were enrolled to dose level 1 (DL1). The planning target volume 1 
(PTV1) comprised the post-operative surgical bed (the thyroid bed, level VI nodal 
group and post-operative nodal groups) and received 58.8 Gy in 28 fractions. 
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The elective nodal levels, PTV2 (remaining level II-V and upper mediastinum) 
received 50 Gy in 28 fractions.  
Dose level 2 (DL2) represented an increase in biologically equivalent dose of 12% 
to the primary tumour, thus delivering 66.6 Gy in 30 fractions to thyroid bed and 
level VI lymph node group, 60 Gy in 30 fractions to post-operative nodal levels 
and 54 Gy in 30 fractions to elective nodal levels.  
 
Radiotherapy Technique 
Patients were immobilised with a custom-made mask. Target volumes and 
organs-at-risk (brainstem, spinal cord and parotid glands) were delineated 
according to ICRU as previously described [6], using a standard protocol across 
both recruiting centres within the same institution (Royal Marsden Hospital) for 
both DL1 and DL2. Radiotherapy was delivered using five or seven-beam 
simultaneous integrated boost IMRT technique. Radiation dose was prescribed 
to the median of the PTV1 dose-volume histogram such that 95% of each PTV 
was encompassed by 95% of the prescription dose.  The maximum dose 
constraints to 1 cm3 of the spinal cord and brainstem were 46 Gy and 54 Gy, 
respectively, and a mean dose constraint of 24 Gy was applied to each parotid 
gland. Radiotherapy was delivered in once daily fractions, 5 fractions weekly 
excluding the weekend. 
 
Outcome assessment 
Recurrence was defined as clinical, biochemical, radiological and/or 
histopathological evidence of disease presenting three months after completing 
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radiotherapy. Where possible, patients proceeded to salvage surgery for 
persistent or recurrent disease. 
 
Acute and late toxicity 
Acute toxicity scores were recorded using NCI-CTCAE v.2.0 weekly during IMRT, 
for 4 weeks of recovery and at week 14. Indications for enteral feeding were: 
weight loss >10%, risk of aspiration and inability to maintain adequate calori fic 
intake. Late toxicity scores (RTOG/EORTC and LENTSOMA) were recorded at 
follow-up at 3, 6, 12, 18 and 24 months after radiotherapy and yearly thereafter 
to 60 months. 
 
Statistical analysis 
The primary endpoint was the number of patients with G3/4 complication at 12 
months after treatment. DL1 was designed as a feasibility study of modestly 
accelerated IMRT equivalent to 60 Gy in 30 fractions. Dose-escalation to DL2 was 
scheduled once feasibility was demonstrated. The stopping rules determined 
that if 0 (n=15) patients had ≥ G3 late complications at 1 year then a ≥  20% risk 
of G3 late complication rate would be excluded with 95% power. If any patient 
developed ≥ G3 late complications at DL1 and DL2, then the number of patients 
recruited at that level would be increased to 30 to improve statistical power and 
escalation to DL2 would only be allowed if no more than two patients developed 
G3 late toxicity (incidence of ≥ G3 late complication rate predicted to be 0-17% 
and 0-22%, respectively, with 95% power).  
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If more than 2 patients suffered a ≥ G3 late complication then recruitment to 
that level would be stopped (incidence of ≥ G3 complication predicted to be 2–
27% with 95% power). The dose-limiting toxicity was defined as the number of 
patients with ≥ G3 toxicity at 1 year following completion of treatment. The 2 
dose cohorts are sequential studies and their outcomes are reported separately.  
Descriptive statistics are used to present the data. The incidence of an acute or 
late toxicity was defined as the total number of patients reaching that grade at 
any time, divided by the total number of assessable patients. The prevalence of 
a reaction at a specified point in time was defined as the number of patients 
scored as having that grade of reaction relative to the total number of patients 
assessed at that specific time point. Outcome measures following IMRT were 
described by local (at primary site) and regional (neck and upper mediastinum) 
control. Time to locoregional recurrence interval was calculated as time from 
diagnosis to recurrent local or nodal disease. Patients with persistent disease at 
primary site or neck were included as locoregional events. Time to relapse 
interval was defined as time from diagnosis to development of locoregional 
and/or distant disease. Overall survival (OS) was measured from diagnosis to 
death from any cause. Survival analyses were estimated using the Kaplan-Meier 
method. All outcomes were recorded at patient visits or gained retrospectively from 
patient records.  
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Results 
 
From February 2002 to December 2010, 15 patients were treated in DL1 and 30 
in DL2 as outlined in the CONSORT diagram (Figure 1). One patient with 
anaplastic thyroid cancer was removed from analysis in DL2. Baseline 
demographics (Table 1) were comparable between the groups. All patients 
underwent total thyroidectomy with selective neck dissection or optimal surgical 
resection of recurrent disease. Radioiodine remnant ablation was administered 
as indicated for differentiated thyroid carcinoma. Median (range) time to 
complete radiotherapy was 38 days (37-45) in DL1 and 42 days (39-46) in DL2. 
 
All 15 patients in DL1 completed radiotherapy without any interruptions. At 12 
months following completion of radiotherapy, 12 patients were assessable for 
late toxicities.  
One patient experienced G3 ‘subjective difficulty in breathing’ at twelve months, 
which resolved and was not reported after this. There was no associated 
respiratory toxicity in the ‘objective’ and ‘management’ domains at any point. 
They had previously experienced G3 dysphagia, pain and salivary gland changes 
during radiotherapy at week 5 and 6 extending to week 2 and 3 post-
radiotherapy. Therefore, after case review it was felt safe to proceed to DL2.  
 
 
Fifteen patients were initially enrolled in DL2. One patient experienced G3 
dysphagia and a radiation-induced stricture at 12 months. The cohort was then 
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expanded to 30 patients. A total of 24 patients were assessable for late toxicities 
at 12 months. A further patient experienced G3 xerostomia that resolved by the 
next visit at 18 months. The two patients who experienced G3 toxicities at 12 
months were alive at 5 years with no evidence of relapse.  
An additional patient experienced G3 dysphagia requiring enteral feeding at the 
end of treatment until 6 months. At 11 months the patient developed wheeze 
and subglottic stenosis that settled with steroids. This deteriorated by 18 
months requiring a tracheostomy. At 24 months they required a laryngectomy 
and unfortunately, the patient died from haemorrhage shortly after. 
 
 
There was no significant difference in the frequency of ≥ G3 toxicities between 
DL1 (8.3%) and DL2 (8.3%) at twelve months (Figure 2). 
This remained the case out to year 5 with three patients reporting xerostomia in 
DL1 and one developing skin fibrosis in DL2 (supplementary material: Table 1, 
Figure 1). 
Tables 2 and 3 (supplementary material) report the number of patients who had at 
least one G3 /4 toxicity at each visit at which toxicity was assessed. 
Tables 4, 5, 6 and 7 (supplementary material) display the total frequency for each 
category of toxicity. During the five years of follow-up, a total of 12 ≥ G3 late 
toxicities occurred for DL1 and 24 for DL2. This includes patients who had the same 
persistent toxicity recorded several times.  
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The number of patients with recorded data at each visit is shown in table 8 
(supplementary material), deaths included: two patients in DL1 during year one, one 
due to a non-cancer cause and the other due to cancer progression. A further three 
died in the third year of follow-up due to disease relapse (supplemental material: 
Figure 2a). 
Two patients in DL2 were lost to follow-up after 6 months. Four patients died within 
the follow-up period, all due to disease relapse.  
In DL1, there were 3 locoregional recurrences (supplemental material: Figure 
2b). Five patients developed metastatic disease (3 medullary, 1 papillary and 1 
Hurthle cell). 
In DL2, two patients developed recurrent disease within the high-dose irradiated 
volume; both had macroscopic residual disease at the time of radiotherapy and 
relapsed within 3 months following completion of radiotherapy. Four patients in 
DL2 developed metastatic disease (1 medullary, 1 recurrent papillary, 1 
undifferentiated small cell/papillary and 1 recurrent Hurthle cell). 
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Discussion 
 
External beam radiotherapy has been used in thyroid cancer for over fifty years, 
although the patient group that benefits from it has been the subject of much 
debate. There has been no successful randomized controlled trial to address this and 
the majority of evidence informing its use has been derived from retrospective 
analyses. Key evidence from trials such as Farahati et al (1996) [8] suggested 
radiotherapy increased the time to relapse in high-risk individuals who were aged 
over 40 with extrathyroideal extension treated standardly with surgery, radioiodine 
ablation and TSH suppression. 
On the basis of reviews into the retrospective data, the British Thyroid Association 
[1] and American Thyroid Association [9] support the use of radiotherapy in selected 
high-risk groups, such as those with significant macroscopic disease or where further 
surgery or radioiodine is not an option. 
 
Dose-response has been investigated over the past 2 decades; Ford et al (2003) [3] 
noted an improved loco-regional control rate as doses rose to over 54 Gy in 
retrospective analysis.   
More recently, IMRT has been used to deliver homogeneous radiotherapy doses 
with steeper dose gradients. Schwartz et al (2009) [4] reported their single 
institution experience in MD Anderson using doses of 60 Gy to the post-operative 
bed with boosts up to 70 Gy to areas of microscopic and macroscopic involvement. 
They reviewed 131 patients, 44% of who were treated with IMRT and noted a 
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decrease in severe late morbidity in the IMRT group (2%) compared to the non-IMRT 
group (12%).  
Teriazakis et al (2009) [5] published data from retrospective analysis of 76 patients 
treated between 1989 and 2006, including 47 who received IMRT. Patients received 
59.4-70 Gy (depending on macroscopic involvement), late enteral feeding tube rate 
was 5% and two patients required a long-term tracheostomy due to laryngeal 
oedema; there was no noted difference in toxicity between IMRT and non-IMRT 
patients. Although retrospective analysis suggests that dose-escalation above 60 Gy 
using IMRT is safe, this has not been demonstrated in a randomized trial.  
 
We first evaluated the outcomes in a modestly accelerated course of 58.8 Gy in 28 
fractions (EQD2 of 60 Gy in 30 fractions) using IMRT and then investigated the safety 
of dose-escalation above this. Urbano et al (2007) [6] previously reported the initial 
results of the DL1 cohort demonstrating its safety and rationale for moving onto 
dose-escalation in DL2. The acute toxicities of DL2 previously reported by Zaidi et al 
(2011) [7] were comparable to DL1.   
 
We now report the mature long-term results and have demonstrated that dose-
escalation of 12% (66.6 Gy in 30 fractions) to the thyroid bed can be safely 
performed and is tolerable when compared to a dose of 58.8 Gy in 28 fractions.  
The study has demonstrated similar ≥ G3 toxicity at 12 months in DL1 and DL2. This 
was consistent when patients were followed up to trial completion at five years. 
However, the study was limited by a decrease in number of assessable patients at 
the 12 month primary endpoint (DL1 = 12, DL2 = 24) 
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The recorded long-term toxicities in this trial compare favourably with other studies 
of thyroid dose-escalation as shown in Table 9 (supplemental material). 
These studies had a dysphagia toxicity rate (≥ G2) of 8% to 20%, similar to our 
reported rate of 12% in DL2. Stricture or enteral-feeding dependence ranged from 
5.4% to 10% compared to 4% in DL2. There was one patient (8%) on nutritional 
supplements in DL1 but none required long-term enteral feeding.  
Although the rates of ≥ G3 toxicities were similar between DL1 and DL2, more 
subjects in DL2 had persistent grade 1 subjective difficulty in eating solids (DL1: 10% 
v DL2: 25%). Although low grade, this toxicity may be due to the dose-escalation. 
There was also one toxicity-related death after 24 months after laryngectomy for 
radiation-induced stricture. This serves to remind us of the need for accurate target 
volume delineation and good patient selection to minimize the normal tissue 
irradiated. It is reassuring that dysphagia-related toxicities for the remaining patients 
in DL2 were similar to other studies, as noted above. 
 
Xerostomia at 5 years was higher in DL1 (33% experienced ≥ G3), however this was a 
small sample (3 out of 9 patients) and it is possible that improvements in 
radiotherapy planning technique with an increasing focus on parotid-sparing IMRT 
may account for this improvement. 
 
Survival outcomes were generally better in DL2 with 5-year overall survival of 83.7% 
in DL2 and 65.5% in DL1. This compares favourably with other series (overall survival 
rates = 54-73%, supplementary material, Table 9).  
 16 
The lower overall survival in DL1 compared to DL2 may be accounted for by the older 
age of its subjects (DL1: 55 v DL2: 52) and the increased number of T4 cases (DL1: 
80% v DL2: 41%). However, there were more node positive cases in DL2 (DL1: 53% v 
DL2: 93%). 
DL2 also had better 5-year time to relapse (DL1: 70.4% v DL2: 79.6%, Figure 3) and 
time to locoregional recurrence than DL1 (DL1: 76.9% v DL2: 91.5%). This difference 
was not statistically significant and it must be noted that the trial was neither 
designed nor powered to detect these outcomes (Table 2).  
 
It would be interesting to assess if the higher overall survival and time to relapse 
noted in DL2 could achieve statistical significance in an adequately powered phase III 
trial. 
This study was hindered by the small sample size and long accrual time with 
subsequent patient drop out and loss of information at follow up visits. 
 
Despite this we have provided evidence that investigation into dose escalation can 
be performed safely, however the long term toxicity of radiotherapy remains a 
concern and current research options are evaluating alternative strategies aimed at 
enhancing the effectiveness of radioiodine in patients using drugs such as 
selumetinib [10], a MEK inhibitor, in trials including the US based ASTRA trial 
(NCT01843062) [11].  
 
The continuing evolution of intensity-modulated radiotherapy provides new 
opportunities to create steep dose gradients. This combined with careful delineation 
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of planning target volumes and organs at risk allows for potential sparing of 
important structures causing long-term toxicity such as the swallowing muscles. This 
concept is already being realised in oropharyngeal and hypopharyngeal cancer 
through the UK DARS trial (ISRCTN 25458988). This is evaluating the impact of 
reducing dose to the pharyngeal constrictor muscles that are involved in swallowing 
on long-term swallowing outcomes in an international, multicentre phase III setting 
[12]. Future phase III thyroid radiotherapy studies could utilize these improved 
techniques with dose escalation to minimize toxicity while ensuring accurate dose 
delivery to planning target volumes.  
 
 
Dose-escalation for thyroid cancer can be safely performed with a toxicity profile 
similar to conventional radiotherapy dose-fractionation schedules and should be 
investigated in further clinical trials. 
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Figures 
 
 
Figure 1: CONSORT diagram 
 
Figure 2: LENTSOMA toxicity at 12 months (%).  
 
Figure 3: Kaplan-Meier estimates of time to relapse interval at 2 and 5 years  
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: 
DL1 = Dose level 1 
DL2 = Dose level 2 
G0, G1.. = Grade 0 toxicity, Grade 1 toxicity etc. 
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CONSORT Diagram 
 
 
 
 
 
 
 
 
 
 
Primary endpoint analysis: n = 12 
 
Incomplete data:  
12 months:  n= 3, 2 due to death, 1 lost to 
follow-up 
60 months:  n= 5, all due to death 
 
 
Allocated to intervention (n= 15) 
 Received allocated intervention (n= 15) 
 
Incomplete data:  
12 months:  n= 6, 3 due to death, 3 lost to 
follow-up 
60 months: n= 15, 4 due to death, 10 lost 
to follow-up 
follow-up  
 
Allocated to intervention (n= 30) 
 Received allocated intervention (n= 30) 
 
Primary endpoint analysis: n = 24 
 Excluded from analysis (n= 1, anaplastic 
carcinoma, died at 6 months) 
 
 
Dose Level I Dose Level 2 
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Figure 2: LENTSOMA toxicity at 12 months (%). 
DL1 (n=12)        DL2 (n=24) 
 
 
No significant difference in frequency of ≥ Grade 3 toxicity at 12 months (DL1 and DL2 = 8.3%).  
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Figure 3: Kaplan-Meier survivor estimates of time to relapse interval at 2 and 5 
years (p=0.33).  
 
Dose Level 1      
   Dose Level 2 
  
 
 
 
 
Figure in bracket = number who have relapsed  
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Table 1: Baseline demographics (n=44) 
Table 2:  Two and five year survival & recurrence outcomes 
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Table 1: Baseline demographics (n=44) 
  
DL1 (n=15) DL2 (n=29) 
n % n % 
Female 10 67 13 45 
Male 5 33 16 55 
pT1 0 0 3 10 
pT2 0 0 10 34.5 
pT3 3 20 4 14 
pT4a 9 60 10 34.5 
pT4b 3 20 2 7 
pN0 7 47 2 7 
pN1a 1 6 10 34 
pN1b 7 47 17 59 
Total 15 100 29 100 
WHO performance status = 0 14 93 23 79 
WHO performance status = 1 1 7 6 21 
Histology 
    
Medullary 7 47 14 48 
Papillary 5 33 14 48 
Follicular 1 7 0 0 
Hurthle cell 2 13 1 4 
Mean Age (SD) 55.1 (12.0) 51.8 (10.6) 
 
SD = standard deviation 
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  Table 2: Two- and five-year survival and recurrence outcomes 
Category 
Dose Level number of patients* 
number of events in 5 
years Log- rank p-value 
2-year survival (95% CI) 5-year survival (95% CI) 
Overall survival (OS) 
DL 1 15 5 
0.09 
73.3 (43.6, 89.1) 65.5 (36.0, 84.0) 
DL 2 29 4 92.9 (74.4, 98.2) 83.7 (62.2, 93.5) 
Time to relapse 
interval 
DL 1 15 4 
0.33 
78.6 (47.3, 92.5) 70.4 (39.0, 87.70) 
DL 2 29 5 85.7 (66.3, 94.4) 79.6 (57.7, 91.0) 
Time to locoregional 
recurrence interval 
  DL 1 15 3 
0.23 
85.2 (52.6, 96.0) 76.9 (44.2, 91.9) 
DL 2 29 2 92.9 (74.4, 98.2) 91.5 (70.1, 97.8) 
 
CI = confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
